Plasma p ‐tau217 in relation to mild behavioral impairment: implications for early detection of Alzheimer's disease

Abstract

Background: The 2024 NIA‐AA revised criteria define Alzheimer's disease (AD) biologically through core biomarkers amyloid‐beta (Aβ) and tau. While cognitive function remains central to the clinical evaluation of early‐stage dementia, mild neurobehavioral changes may coexist and even precede cognitive decline.